{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:22Z","timestamp":1793647582513,"version":"4.5.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.otc.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:06:13Z","timestamp":1759521973000},"page":"211-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Treatment Approaches in Recurrent\/Metastatic Squamous Head and Neck Cancer"],"prefix":"10.1016","volume":"59","author":[{"given":"Sandra","family":"Llop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Jim\u00e9nez-Labaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Micheletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primer"},{"issue":"10","key":"10.1016\/j.otc.2025.08.009_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/annonc\/mdx304","article-title":"Human papillomavirus-related oropharyngeal cancer","volume":"28","author":"Taberna","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib4","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib5","article-title":"Head and neck cancer","volume":"382","author":"Lqm","year":"2020","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.otc.2025.08.009_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.otc.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.otc.2025.08.009_bib8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.bjc.6605697","article-title":"Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment","volume":"102","author":"Martinez-Trufero","year":"2010","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.otc.2025.08.009_bib9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3109\/00016480802590451","article-title":"Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients","volume":"129","author":"Grau","year":"2009","journal-title":"Acta Otolaryngol"},{"issue":"19","key":"10.1016\/j.otc.2025.08.009_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10167","key":"10.1016\/j.otc.2025.08.009_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.otc.2025.08.009_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.otc.2025.08.009_bib13","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.3390\/ijms23147889","article-title":"Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma","volume":"23","author":"Ghosh","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.otc.2025.08.009_bib14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.otc.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.otc.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"10.1016\/j.otc.2025.08.009_bib17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007573","article-title":"Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites","volume":"12","author":"Muijlwijk","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.otc.2025.08.009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.107145","article-title":"Immunotherapeutic strategies beyond the PD-1\/PD-L1 pathway in head and neck squamous cell carcinoma - a scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA","volume":"161","author":"Struckmeier","year":"2025","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.otc.2025.08.009_bib20","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ijrobp.2024.01.019","article-title":"A phase II trial of personalized immunotherapy in patients (pts) with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (R\/M HNSCC) that have progressed on prior immunotherapy","volume":"118","author":"Zandberg","year":"2024","journal-title":"Int J Radiat Oncol"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib21","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1200\/JCO.2024.42.16_suppl.6038","article-title":"A phase 1 study of fianlimab (anti\u2013LAG-3) in combination with cemiplimab (anti\u2013PD-1) in patients with advanced HNSCC","volume":"42","author":"Cho","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6028","article-title":"Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma","author":"Brana","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib23","first-page":"1","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.otc.2025.08.009_bib24","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.otc.2025.08.009_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/PPO.0000000000000621","article-title":"HPV-Directed therapeutics for HPV-associated oropharyngeal cancer","volume":"28","author":"Campbell","year":"2022","journal-title":"Cancer J Sudbury Mass"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.otc.2025.08.009_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004232","article-title":"ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response","volume":"10","author":"de Sousa","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.otc.2025.08.009_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.940","article-title":"879P VERSATILE-002: survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC)","volume":"35","author":"Weiss","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib30","author":"Feed"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib31","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1200\/JCO.2023.41.16_suppl.6013","article-title":"A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent\/metastatic HPV16+ head and neck cancer","volume":"41","author":"Chung","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.otc.2025.08.009_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","article-title":"Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus\u2013associated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.otc.2025.08.009_bib33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cas.14784","article-title":"Personalized cancer vaccination in head and neck cancer","volume":"112","author":"Shibata","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.otc.2025.08.009_bib34","volume":"34","author":"Mach","year":"2023","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"10.1016\/j.otc.2025.08.009_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2018.36.5_suppl.115","article-title":"Effect of therapeutic vaccine on CTLA4 and tumor debulking response in recurrent and metastatic HNSCC","volume":"36","author":"Chindavijak","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.otc.2025.08.009_bib36","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2021.39.15_suppl.2613","article-title":"Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors","volume":"39","author":"Gillison","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.otc.2025.08.009_bib37","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.3092","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","author":"Patel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.otc.2025.08.009_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl_12","key":"10.1016\/j.otc.2025.08.009_bib39","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3 Pt 1","key":"10.1016\/j.otc.2025.08.009_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/000348940411300312","article-title":"Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors","volume":"113","author":"Duvillard","year":"2004","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9","key":"10.1016\/j.otc.2025.08.009_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.ejso.2005.04.007","article-title":"The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck","volume":"31","author":"Bloom","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"15","key":"10.1016\/j.otc.2025.08.009_bib42","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","article-title":"Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib43","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2023.41.16_suppl.2520","article-title":"A phase 1\/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors","volume":"41","author":"Ji","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.otc.2025.08.009_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.otc.2025.08.009_bib45","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2008.17.8251","article-title":"Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms","volume":"27","author":"Lai","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.otc.2025.08.009_bib46","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1002\/cncr.31651","article-title":"Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives","volume":"124","author":"Bauman","year":"2018","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.otc.2025.08.009_bib47","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.otc.2025.08.009_bib48","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/biomedicines11082097","article-title":"Combining radiotherapy and immunotherapy in head and neck cancer","volume":"11","author":"Runnels","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.otc.2025.08.009_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102746","article-title":"Intratumoral therapies in head and neck squamous cell carcinoma: a systematic review and future perspectives","volume":"127","author":"Jim\u00e9nez-Labaig","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40644-024-00763-y","article-title":"Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations","volume":"24","author":"Bitar","year":"2024","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib51","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.otc.2025.08.009_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.otc.2025.08.009_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific antibody use in patients with lymphoma and multiple myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.otc.2025.08.009_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/PPO.0000000000000619","article-title":"c-Met signaling as a therapeutic target in head and neck cancer","volume":"28","author":"Centuori","year":"2022","journal-title":"Cancer J"},{"issue":"7_Supplement","key":"10.1016\/j.otc.2025.08.009_bib55","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/1538-7445.AM2023-5865","article-title":"Abstract 5865: combinatorial activity of amivantamab and pembrolizumab in head and neck squamous cell carcinoma and lung squamous cell carcinoma expressing wild-type EGFR and MET","volume":"83","author":"Lim","year":"2023","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.otc.2025.08.009_bib56","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oooo.2014.11.014","article-title":"LGR5 expression in oral epithelial dysplasia and oral squamous cell carcinoma","volume":"119","author":"Dalley","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"11","key":"10.1016\/j.otc.2025.08.009_bib57","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-21-4425","article-title":"BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGF\u03b2 signaling to durably suppress tumor growth","volume":"83","author":"Boreddy","year":"2023","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib58","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1200\/JCO.2023.41.16_suppl.6005","article-title":"Dose expansion results of the bifunctional EGFR\/TGF\u03b2 inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib59","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1016\/j.annonc.2023.09.2000","volume":"34","author":"Fayette","year":"2023","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib60","doi-asserted-by":"crossref","first-page":"TPS6120","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6120","article-title":"eVOLVE-HNSCC: a global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT)","volume":"42","author":"Haddad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib61","article-title":"160TiP Safety and antitumor activity of GEN1042 in combination with pembrolizumab \u00b1 chemotherapy in solid tumors: phase IIb dose-expansion trial in progress","volume":"20","author":"Melero","year":"2023","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.otc.2025.08.009_bib62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib63","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1200\/JCO.2023.41.16_suppl.9126","article-title":"Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: the PALOMA study\u2014updated safety and identification of the recommended phase 2 dose","volume":"41","author":"Minchom","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.otc.2025.08.009_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and Mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.otc.2025.08.009_bib65","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti\u2013epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.otc.2025.08.009_bib66","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib67","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.otc.2025.08.009_bib68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14728214.2022.2125954","article-title":"Emerging tyrosine kinase inhibitors for head and neck cancer","volume":"27","author":"Long","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"10.1016\/j.otc.2025.08.009_bib69","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2024.01.016","article-title":"Pembrolizumab with or without lenvatinib as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): phase 3 LEAP-010 study","volume":"118","author":"Licitra","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.otc.2025.08.009_bib70","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41591-023-02275-x","article-title":"Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial","volume":"29","author":"Saba","year":"2023","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.otc.2025.08.009_bib71","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1158\/1078-0432.CCR-24-1202","article-title":"Pembrolizumab and cabozantinib in recurrent and\/or metastatic head and neck squamous cell carcinoma: long-term survival update with a biomarker analysis","volume":"30","author":"Saba","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"17","key":"10.1016\/j.otc.2025.08.009_bib72","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"10.1016\/j.otc.2025.08.009_bib73","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.22.01994","article-title":"Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, recurrent\/metastatic head and neck cancer","volume":"41","author":"Bauman","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.otc.2025.08.009_bib74","article-title":"A phase Ib\/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent\/metastatic head and neck squamous cell carcinoma (RM-HNSCC): updated results","volume":"29","author":"Cohen","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"16_suppl","key":"10.1016\/j.otc.2025.08.009_bib75","doi-asserted-by":"crossref","first-page":"TPS6113","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6113","article-title":"PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and\/or metastatic head and neck squamous cell carcinoma (RM HNSCC)","volume":"42","author":"Posner","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666525001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666525001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:31:01Z","timestamp":1772857861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666525001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0030666525001136"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2025.08.009","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Treatment Approaches in Recurrent\/Metastatic Squamous Head and Neck Cancer","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}